This $1,521,607 Project Grant award from the National Institutes of Health's (NIH) Research Infrastructure Programs (CFDA 93.351) will provide Emory University with an automated robotic culture system to enhance the capabilities of their Organoid Hub. The Organoid Hub aims to standardize and scale the production of various organoid types, including brain, gut, cardiac, and kidney organoids, to facilitate advanced 3D cell culture research. The automated system will reduce hands-on time,...
The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
The Stanford University received a three-year $2.83 million Project Grant from the Department of Health and Human Services National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant will support development of novel methods to dramatically reduce the cost of stem cell maintenance and increase the scale of organoid production for organ biofabrication applications. Specifically, the university will engineer growth factor-free human...
Rattan Life Science Inc. received a $275,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a platform for generating induced pluripotent stem cell-derived naïve CD4+ and CD8+ T cells with fidelity, reproducibility and scalability. The platform employs proprietary induced thymic epithelial cells to provide biologically relevant thymic positive selection signals during T cell differentiation,...
This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $178,000.00 to Boston Children's Hospital to develop a bone marrow organoid system to study the rare genetic disorder RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy (RUNX1-FPD/MM). The 1-year project aims to generate bone marrow organoids from patient-derived induced pluripotent stem cell lines, both with and without the RUNX1 genetic mutation, to recapitulate the...
This $250,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant supports the development of artificial substrates for growing human stem cells suitable for clinical applications at Oakland University from March 2023 to February 2025. The goal is to accelerate the potential benefits of using human pluripotent stem cells and their derivatives for treating and curing diseases by producing a synthetic substrate that supports growth of human pluripotent stem cells...
This Project Grant award from the National Institute on Deafness and Other Communication Disorders (CFDA 93.173) provides $767,494 to the University of Miami to develop human induced pluripotent stem cell-derived inner ear organoid platforms for modeling and treating genetic hearing loss and vestibular disorders. The key objectives are to: 1) Establish and optimize 3D inner ear organoid systems from patient-derived pluripotent stem cells, and 2) Test in vitro CRISPR/Cas9-based gene disruption...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to improve the robustness and reproducibility of differentiating human pluripotent stem cells (hPSCs) into cardiomyocytes (CMs) through the development of feedback-controlled closed-loop manufacturing processes. The key objectives are to: 1) Identify 2D CM differentiation failure modes through integrated single-cell transcriptomics...
This $443,576 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to develop a 3D bioengineered tooth regeneration system using human induced pluripotent stem cells (hiPSCs). The University of Washington, as the primary awardee, aims to: 1) Investigate how the material composition and mechanical properties of a chitosan-alginate scaffold regulate hiPSC renewal and...